The New 2026 season of Buck podcast “We’re not getting any younger…yet” launches tomorrow! 1st episode features Harvard geneticist George Church, one of the most provocative thinkers in the longevity field. Available wherever you get your podcasts. Subscribe - don’t miss single episode!
2 Likes
1 Like
Tony Wyss-Coray: Rejuvenating the Brain
Gemini Pro AI Video Summary
Executive Summary
This dialogue between Dr. Eric Verdin (CEO of the Buck Institute) and Dr. Tony Wyss-Coray (Stanford University) explores the evolution of geroscience from foundational “young blood” experiments to the current frontier of organ-specific proteomic clocks. The conversation transitions from the historical context of heterochronic parabiosis—the surgical joining of young and old mice to share circulation—to the practical application of these findings in human medicine through therapeutic plasma exchange (TPE).
A central thesis presented is that aging is not a monolithic, synchronized process across the entire body. Instead, individual organs age at different rates. Wyss-Coray argues that measuring “biological age” for the whole person is insufficient for clinical intervention; instead, clinicians must measure organ-specific age to treat pathologies before they manifest as irreversible disease. By utilizing high-throughput proteomics (measuring thousands of proteins in the blood), his team has identified “organ-specific” protein signatures that leak into the circulation. These signatures allow for the calculation of an “Age Gap”—the deviation between chronological age and the biological age of a specific organ.
Specifically regarding neurodegeneration, the discussion challenges the notion that the “Amyloid Hypothesis” has failed, suggesting instead that interventions have simply been administered too late. Proteomic markers, such as the brain-specific aging signature found in the UK Biobank study, can predict Alzheimer’s risk up to 15 years before clinical symptoms emerge. The researchers highlight a 20-fold difference in Alzheimer’s risk between those with the “youngest” vs. “oldest” brains and note that a “young brain” correlates with an 80% reduction in overall mortality.
The dialogue concludes with a vision for preventative medicine 2.0, where biannual proteomic profiling provides a “dashboard” of organ health, enabling personalized lifestyle or pharmacological interventions (e.g., targeting the immune system or gut barrier) decades before traditional diagnostic thresholds are met.
Bullet Summary
- Heterochronic Parabiosis: Early mouse studies proved that young blood circulation can rejuvenate muscle stem cells and improve cognitive function in older mice.
- Systemic Environment: Aging is driven significantly by the systemic environment (blood), not just intrinsic cellular decay.
- Detrimental Factors: Factors like Eotaxin (CCL11) and Beta-2 Microglobulin (B2M) accumulate in old blood and actively impair brain function and neurogenesis.
- Rejuvenation vs. Dilution: Benefits of plasma exchange likely come from both adding beneficial “young” factors and diluting “pro-aging” inflammatory factors.
- Organ-Specific Aging: Organs age at different rates; a person might have a “young” heart but an “old” brain.
- Proteomics over Epigenetics: While epigenetic clocks are popular, proteomics (measuring proteins) provides a more direct readout of current functional biology and “organ suffering.”
- The “Age Gap”: The difference between your actual age and your organ’s biological age is a more powerful predictor of disease than chronological age.
- Brain Age & Alzheimer’s: A proteomic “old brain” signature predicts Alzheimer’s onset 15 years in advance.
- Predictive Power: Individuals with the youngest brains in the UK Biobank study showed an 80% reduction in 15-year mortality.
- The Amyloid Reconciliation: Amyloid and Tau are critical, but anti-amyloid drugs fail because they are given to patients whose “arteries are already obliterated” (advanced disease).
- Immune-Brain Axis: Brain health is deeply tied to systemic immunity; activating the immune system can modulate amyloid pathology.
- Gut-Brain Connection: The gut holds 50% of the immune system; gut barrier permeability (leaky gut) is a primary driver of systemic inflammation affecting the brain.
- Early Intervention: The future of medicine involves treating “organ aging” 10–20 years before a diagnosis like Parkinson’s or Alzheimer’s.
- Scalability: Current proteomic platforms can measure 3,000 to 7,000 proteins in a single plasma sample with high reproducibility.
- Direct Feedback: Unlike genetic testing (fixed risk), proteomic clocks provide a “live” feedback loop to see if diet, exercise, or drugs are actually working.
Claims & Evidence Table (Adversarial Peer Review)
| Claim from Video | Speaker’s Evidence | Scientific Reality (Best Available Data) | Evidence Grade (A-E) | Verdict |
|---|---|---|---|---|
| Young blood rejuvenates old brain/muscle. | Cites Rando/Wyss-Coray parabiosis studies in mice. | Replicated in multiple labs; Nature 2014. However, human “young plasma” trials for AD (PLASMA study) showed safety but lacked robust efficacy. | D (Animal) / B (Human-Small) | Plausible/Translational Gap |
| Proteomic clocks predict Alzheimer’s 15 yrs early. | Nature paper (Dec 2023) and UK Biobank data (50k people). | Supported by Oh et al., Nature 2023. Highly accurate in large cohorts but requires prospective validation in clinical settings. | C (Cohort/Observational) | Strong Support |
| Eotaxin (CCL11) causes brain aging/fog. | Wyss-Coray lab research; Michelle Monje studies on chemo-fog. | Villeda et al., 2011 identified CCL11 as a pro-aging factor in mice. Human correlation exists, but RCTs blocking CCL11 are pending. | D (Animal/Mechanistic) | Speculative (Animal Data) |
| Young brain = 80% lower mortality. | UK Biobank analysis (3,000+ proteins). | Statistical correlation in Nature 2023. Remarkable hazard ratio, but “young brain” may be a proxy for overall systemic health. | C (Cohort) | Plausible |
| TPE/Plasma Exchange reverses aging clocks. | Verdin mentions a study using “a number of clocks.” | Kiprov et al., 2022 showed TPE reduces inflammatory markers and shifts some clocks, but “reversal” is a heavy term; “modulation” is more accurate. | B (Human RCT/Pilot) | Plausible (Emerging Data) |
Actionable Insights (Pragmatic & Prioritized)
Top Tier (High Confidence)
- Prioritize Gut Barrier Integrity: Focus on diet (high fiber) to maintain the gut-vascular barrier. Since 50% of the immune system is in the gut, “leaky gut” directly facilitates the entry of inflammatory factors that accelerate brain aging.
- Early Biomarker Screening: If available via boutique clinics (e.g., Grail, Fountain Life, or specialized proteomic providers), monitor organ-specific markers (Liver, Kidney, Brain) rather than just “whole body” biological age.
- Manage Systemic Inflammation: Since brain aging is driven by systemic factors (Eotaxin, B2M), interventions that lower chronic systemic inflammation (exercise, sleep, weight management) are neuroprotective.
Experimental (Risk/Reward)
- Therapeutic Plasma Exchange (TPE): For those with significant inflammatory burdens or early signs of cognitive decline, TPE (diluting “old” plasma) is an emerging clinical protocol with a high safety profile, though currently expensive and not yet standard of care for longevity.
- Proteomic “Age Gap” Testing: Utilize services that measure the “Age Gap” to identify which specific organ system is the “weakest link” in your longevity profile.
Avoid
- Late-Stage “Cures”: Do not rely on “reversing” neurodegeneration once clinical symptoms are advanced. The dialogue emphasizes that by the time Alzheimer’s is diagnosed, the “arteries are already obliterated.” The focus must be on the 15-year window before symptoms.
Technical Deep-Dive
The mechanism discussed centers on Proteomic Organ Mapping. This utilizes the fact that nearly every organ sheds a small percentage of its proteome into the blood. By cross-referencing blood proteins with GTEx (Genotype-Tissue Expression) data, researchers identified proteins that are highly enriched (e.g., 4-fold higher) in specific organs.
- Machine Learning Models: LASSO or similar regression models are trained to predict chronological age based on these organ-specific proteins in healthy populations.
- Deviance Analysis: When an individual’s protein levels suggest they are 70 years old while they are chronologically 60, they possess a +10 year Age Gap.
- Pathophysiological Leaking: The “leaking” of organ-specific proteins (like troponin in the heart or transaminases in the liver) is not just a sign of acute damage but a chronic indicator of the cellular senescence and tissue remodeling associated with aging.
Knowledge Gap: We do not yet know if aggressively lowering a specific “old” protein (like CCL11) in humans will yield the same cognitive gains seen in mice. Most data remains correlational (Level C).
1 Like